Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaMichael J. Keating, Hagop M. Kantarjian, Susan O’Brien et al.|Journal of Clinical Oncology|2005Cited by 951
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Francis J. Giles, Ayush Arya et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 468
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateElias Jabbour, Jörge E. Cortes, Hagop M. Kantarjian et al.|Leukemia|2006Cited by 387
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Megan Othus et al.|Clinical Cancer Research|2020Cited by 326